Biocom - Life Sciences Association of California
San Diego  |   Los Angeles  |   Washington, DC  |   Tokyo


Partnering Day with Boehringer Ingelheim

Championing Innovation in San Diego: Boehringer Ingelheim Partnering Day - September 21st 2017 

Boehringer Ingelheim knows what it takes to be innovative and entrepreneurial. From the small factory in 1885 to today’s multi-billion-dollar global pharmaceutical organization, we know how important it is to nurture and develop young science and technology businesses. Our track record of bringing breakthrough medicines to patients starts with new ideas and new science. And collaborations with external partners play an essential role in helping us deliver an innovation-led portfolio. We look forward to meeting you at our partnering day so we can learn from each other to develop the next generation of medicines.

Meet our Research and Partnering Team

Our research and partnering leadership teams will be available throughout the day for one-on-one meetings and at our networking reception in the evening:

  • Learn more about our research and partnering interests
  • Hear how our corporate Venture Fund drives innovation through its strategic investment in early-stage science and technology
  • Join our panel discussion and Q&A: ‘Collaborative Science and Partnering with BI’ where representatives from Boehringer Ingelheim, academia and equity investors, together with Boehringer Ingelheim partners, will talk about our approach to research and partnering.

For more details,click here for our full agenda.

PaolaCasarose.jpg CliveWood.jpg MartinHeidecker.png

                                                    Dr. Paola Casarosa, Corporate Vice President, Business Development and Licensing

Dr. Clive Wood, Senior Vice President, Human Pharma Discovery Research 

Dr. Martin Heidecker, Director, Investment Manager of the Boehringer Ingelheim Venture Fund 

Our Partnering Interests

We work closely with all stakeholders in the innovation ecosystem – from pharma to biotechs to academia to starts ups – to help achieve our innovation ambition of delivering meaningful breakthroughs that improve patients’ lives. With industry-leading levels of investment, including 1.5 billion euro designated for external innovation,* we are increasing our emphasis on collaborations and expanding our global network of innovation partners. 

For more information about our specific partnering interests please download our flyers. 

CardioMetabolic diseases

CNS diseases



Respiratory diseases


Research Beyond Borders

*Five-year investment designated 2016-2020

How to Apply

If you are interested in discussing potential opportunities for partnering with the Boehringer Ingelheim team in a one-to-one meeting, please send a one-page non-confidential executive summary to Oscar Rodarte at by September 5, 2017